DE69131249D1 - Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen - Google Patents

Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Info

Publication number
DE69131249D1
DE69131249D1 DE69131249T DE69131249T DE69131249D1 DE 69131249 D1 DE69131249 D1 DE 69131249D1 DE 69131249 T DE69131249 T DE 69131249T DE 69131249 T DE69131249 T DE 69131249T DE 69131249 D1 DE69131249 D1 DE 69131249D1
Authority
DE
Germany
Prior art keywords
proteins
pharmaceutical
human lymphocytes
dna encoding
biological use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131249T
Other languages
English (en)
Other versions
DE69131249T2 (de
Inventor
Thierry Hercend
Frederic Triebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Gustave Roussy (IGR)
Publication of DE69131249D1 publication Critical patent/DE69131249D1/de
Application granted granted Critical
Publication of DE69131249T2 publication Critical patent/DE69131249T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69131249T 1990-01-08 1991-01-08 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen Expired - Fee Related DE69131249T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9000126A FR2656800B1 (fr) 1990-01-08 1990-01-08 Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
PCT/FR1991/000009 WO1991010682A1 (fr) 1990-01-08 1991-01-08 Proteines produites par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques

Publications (2)

Publication Number Publication Date
DE69131249D1 true DE69131249D1 (de) 1999-06-24
DE69131249T2 DE69131249T2 (de) 1999-12-30

Family

ID=9392569

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131249T Expired - Fee Related DE69131249T2 (de) 1990-01-08 1991-01-08 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Country Status (13)

Country Link
US (2) US5773578A (de)
EP (1) EP0510079B1 (de)
JP (1) JP2997053B2 (de)
AT (1) ATE180261T1 (de)
DE (1) DE69131249T2 (de)
DK (1) DK0510079T3 (de)
ES (1) ES2134770T3 (de)
FR (1) FR2656800B1 (de)
GR (1) GR3030811T3 (de)
IL (1) IL96907A (de)
MX (1) MX9203379A (de)
WO (1) WO1991010682A1 (de)
ZA (1) ZA91134B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
AU755030B2 (en) * 1994-05-06 2002-11-28 Institut Gustave Roussy LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
ES2281899T3 (es) * 1994-05-06 2007-10-01 Institut Gustave Roussy Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica; anticuerpo anti-idiotipo.
US6197524B1 (en) * 1995-07-21 2001-03-06 Institute National De La Sante Et De La Recherche Medicale Methods for detecting, identifying, isolating, and selectively labelling and targeting TH1 lymphocyte by means of the LAG-3 protein
ES2225901T3 (es) * 1996-11-29 2005-03-16 Applied Research Systems Ars Holding N.V. Metodos para prevenir el rechazo de injertos en transplante y para producir una celula hospedante universal para terapia genica haciendo uso de activacion linfocitica (lag - 3).
EP0900841A1 (de) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Spleissvarianten von LAG-3
EP0893507A1 (de) 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
JP2002534961A (ja) * 1998-12-18 2002-10-22 インサイト・ファーマスーティカルズ・インコーポレイテッド リンパ球膜タンパク質
SE0103423D0 (sv) * 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
CA2476518A1 (en) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2439580T3 (es) * 2003-02-28 2014-01-23 The Johns Hopkins University Regulación de células T
KR100808925B1 (ko) 2006-09-29 2008-03-03 고려대학교 산학협력단 돼지 ｌａｇ-3 융합 이뮤노글로블린
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP6595458B2 (ja) 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CR20160425A (es) 2014-03-14 2017-05-26 Novartis Ag Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN106999577B (zh) 2014-07-16 2021-12-21 特兰斯吉恩股份有限公司 溶瘤病毒和免疫检查点调节因子组合
EP3552615B8 (de) 2014-07-16 2022-03-02 Transgene Onkolytisches virus zur expression von immunologischen prüfpunktmodulatoren
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
UA127372C2 (uk) 2015-07-30 2023-08-02 Макродженікс, Інк. Моноспецифічне pd-1-сполучне моноклональне антитіло
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
EP3399989B1 (de) 2015-12-16 2023-08-09 Merck Sharp & Dohme LLC Anti-lag3-antikörper und antigenbindende fragmente
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
MA46814B2 (fr) 2017-02-10 2022-09-30 Regeneron Pharma Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
KR20190137911A (ko) 2017-04-21 2019-12-11 신라젠(주) 항암 백시니아 바이러스와 관문 저해제 병용 요법
US11807686B2 (en) 2017-05-30 2023-11-07 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
EP3630179A2 (de) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Zusammensetzungen mit einem anti-lag-3-antikörper oder einem anti-lag-3-antikörper und einem anti-pd-1-oder anti-pd-l1-antikörper
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CA3134439A1 (en) 2019-03-29 2020-10-08 Institut Curie Interleukin-2 variants with modified biological activity
US20220249659A1 (en) 2019-05-13 2022-08-11 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
US20220401539A1 (en) 2019-10-22 2022-12-22 Institut Curie Immunotherapy Targeting Tumor Neoantigenic Peptides
EP3824954A1 (de) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
WO2021234110A1 (en) 2020-05-20 2021-11-25 Institut Curie Single domain antibodies and their use in cancer therapies
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
WO2022084325A1 (en) 2020-10-20 2022-04-28 Institut Curie Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
WO2022106505A1 (en) 2020-11-18 2022-05-27 Institut Curie Dimers of biguanidines and their therapeutic uses
IL304031A (en) 2021-01-14 2023-08-01 Inst Curie Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
WO2023011879A1 (en) 2021-08-05 2023-02-09 Institut Curie Scanning dynamic device for minibeams production
EP4401715A1 (de) 2021-09-17 2024-07-24 Institut Curie Bet-inhibitoren zur behandlung von pab1-defizientem krebs
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023180552A1 (en) 2022-03-24 2023-09-28 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023194608A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
WO2023194607A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2024068617A1 (en) 2022-09-26 2024-04-04 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US4994369A (en) * 1987-12-15 1991-02-19 The Board Of Trustees Of The Leland Stanford Jr. Univ. T-cell activation related gene
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers

Also Published As

Publication number Publication date
US5874250A (en) 1999-02-23
FR2656800A1 (fr) 1991-07-12
ZA91134B (en) 1992-08-26
ES2134770T3 (es) 1999-10-16
MX9203379A (es) 1992-09-01
IL96907A0 (en) 1992-03-29
IL96907A (en) 1998-10-30
JP2997053B2 (ja) 2000-01-11
GR3030811T3 (en) 1999-11-30
US5773578A (en) 1998-06-30
DK0510079T3 (da) 1999-11-29
FR2656800B1 (fr) 1992-05-15
ATE180261T1 (de) 1999-06-15
EP0510079A1 (de) 1992-10-28
WO1991010682A1 (fr) 1991-07-25
EP0510079B1 (de) 1999-05-19
JPH05503520A (ja) 1993-06-10
DE69131249T2 (de) 1999-12-30

Similar Documents

Publication Publication Date Title
DE69131249D1 (de) Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen
ES2142953T3 (es) Factor de crecimiento y diferenciacion de la familia del tgf-beta.
DE69016426D1 (de) Biologische klappenprothese.
DE69012842D1 (de) Extrudierbares elastisches Gel zur Verwendung als Träger für Arzneistoffe.
ES8602121A1 (es) Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana
DE68914664D1 (de) Gereinigte ubiquitin-hydrolase, diese kodierende dns-sequenzen und ihre verwendung zur gewinnung von polypeptiden.
BR9708100A (pt) Proteìna alfa de ativação de fibroblasto dimérico isolado, e seus usos.
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
ATE202570T1 (de) Gene, die für macif proteine kodieren, expressionsvektoren mit diesem genen, und transformantenzellen mit diesem proteinen
DE69728897D1 (de) Saeugetierchemokine
PT676413E (pt) Proteina de ligacao a interferoes alfa/beta, sua preparacao e utilizacao
DE68912536D1 (de) Flüssiges Nahrungsmittel zur Proteinzuführung.
AU4981093A (en) Nucleotide sequences coding for cryptosporidium proteins, polypeptides coded by said sequences and kits for the use thereof
TR26931A (tr) Lak koagülasyonunda molipten bilesiklerinin kullanilmasi.
DE69836278D1 (de) Allele formen von menschlichem stat3
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DE3880486D1 (de) Aspirator zur aufnahme von koerperfluessigkeiten.
DE59611293D1 (de) Protein mit dnase-aktivität
RU95114858A (ru) Новый пептидный фрагмент, обладающий биологической активностью инсулина
DE69033553D1 (de) Rekombinante herstellung von laktoperoxidase
DE59610098D1 (de) Protein mit anti-tumorwirkung
ATE104344T1 (de) Gereinigte ubiquitin-hydrolase, diese kodierende dns-sequenzen und ihre verwendung zur gewinnung von polypeptiden.
ITRM980790A0 (it) Dna copia (cdna) che codifica per una proteina con l'attivita' biologi ca dell'euserratina 4, procedimento per la sua preparazione, suoi usi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee